Needham & Company Reiterates a Buy Rating as GenMark Diagnostics (GNMK) Reports 4Q Results Consistent with Preannouncement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/26/2026

1. ON
2. SYNA
3. SPY
4. MU
5. DRI
6. NKE
7. NVDA
8. FDXF
9. INCY
10. AMAT

Go back to Needham & Company Reiterates a Buy Rating as GenMark Diagnostics (GNMK) Reports 4Q Results Consistent with Preannouncement

GenMark Reports Fourth Quarter and Full Year 2015 Results

February 23, 2016 4:05 PM EST

Fourth Quarter Revenue increased 34% Versus Prior Year to $13.2 million

Fourth Quarter Gross Margin Increased to 64%, and XT-8 Installed Base Grew by 17 to 633

ePlex Production Capacity Increased to Support Upcoming European Launch

Additional Time Likely Required to Address Remaining ePlex Manufacturing Variability

CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2015.

Revenue for the... More